Allied
market research publishes a new report titled “Global Potential
Analysis of Ebola drug and Vaccines Market (Pipeline analysis, Drugs,
Vaccines, and Geography) through 2020.” This report provides
knowledge and deep-insights on the Ebola disease from the time of its
existence. The report is an extensive study on the growing need for Ebola drug market.
Ebola
haemorrhagic fever (EHF) is popularly known as Ebola virus diseases
(EVD). Headaches, muscle pain, sore throat and fever are most common
symptoms seen in an Ebola patient. The disease is more predominant in
western & central Africa and the around the tropical rain forest
region. In terms of geographical analysis, report covers LAMEA, North
America, Asia-Pacific and Europe. African countries have the highest
number of Ebola cases and with the wide presence of African
population in America, the US government is implementing strong
regulations in order to control this disease.
“Additionally,
the governments in the developed countries have also taken formidable
steps to support the research activities for the development of EVD
therapeutics by providing funding and floating favourable policies.
As an example, Tekmira Pharmaceuticals has received fast-track
designation from U.S. food and drug administration for their
anti-ebola therapeutic TKM-ebola. In 2012, Serepata Therapeutics had
also received fast track designation for AVI-7537, a lead drug
candidate for EVD. Both these companies are developing their
anti-ebola products under the contract of the U.S. department of
defence (DoD),” says AMR analysts Roshan Deshmukh.
“Due
to high mortality rate and unavailability of effective treatments,
the pharmaceutical companies have big opportunities to explore.
Tekmira Pharmaceuticals, BioCryst Pharmaceutical Inc., Serepata
Therapeutics, NewLink Genetics and Mapp Biopharmaceutical are some of
the leading companies focusing on research activities to develop
efficacious medicine for EVD,” adds Deshmukh.
